



Handwritten signature

Patent Application
Attorney Docket No. **PC20553A**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: **ELLIOTT, ET AL.** :

APPLICATION NO.: **10/632,281** : Examiner: **C. DELARCROIX-MUIRHEID**

FILING DATE: **AUGUST 1, 2003** : Group Art Unit: **1614**

TITLE: **THERAPEUTIC COMBINATIONS OF ERB:
b KINASE INHIBITORS AND
ANTINEOPLASTIC THERAPIES** :

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO/FB/A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Please charge all appropriate fees to cover this submission to Pfizer Deposit Account No. 16-1445.

A prompt and favorable response is earnestly solicited.

Respectfully submitted,


Date: June 14, 2005

Handwritten signature of Pamela C. Ancona

Pamela C. Ancona, Ph.D.
Attorney for Applicants
Reg. No. 41,494

Pfizer Inc
Patent Department, 5th Floor
150 East 42nd Street
New York, NY 10017-5755
(212)733 -6031

1/1

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				ATTY. DOCKET NO. PC20553A				SERIAL NO. 10/632,281			
				APPLICANT ELLIOTT, ET AL.							
				FILING DATE AUGUST 1, 2003				GROUP 1614			
U.S. PATENT DOCUMENTS											
EXAMINER INITIAL	DOCUMENT NUMBER						DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
			8	1	2	2	3	08/28/01	Choy et al.		
		6	1	4	7	1	0	7	11/14/00	Dent et al.	
FOREIGN PATENT DOCUMENTS											
DOCUMENT NUMBER						DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
										YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)											
			PCT International Search Report, PCT/IB02/03388								
			Ciardiello et al., Expert Opinion on Investigational Drugs, Vol. 11, No. 6, 2002, pages 755-768								
			Erichman et al., Cancer Research, Vol. 61, No. 2, 2001, pages 739-748								
			Gieseg et al., Anti-Cancer Drugs, Vol. 12, No. 8, 2001, pages 683-690								
			Nelson et al., The Journal of Biological Chemistry, Vol. 276, No. 18, 2001, pages 14842-14847								
			Rao et al., Int. J. Radiation Oncology Biol. Phys., Vol. 48, No. 5, 2000, pages 1519-1528								
			Zhang et al., Proceedings of the American Association for Cancer Research, Vol. 42, 2001, page 131								
			Ciardiello et al., Clinical Cancer Research, Vol. 6, No. 5, 2000, pages 2053-2063								
			Slichenmyer et al., Seminars in Oncology, Vol. 28, No. 5, Suppl. 16, 2001, pages 80-85								
			Belani et al., Journal of Clinical Oncology, Vol. 17, No. 2, 1999, pages 676-684								
			Shin et al., Clinical Cancer Research, Vol. 7, 2001, pages 1204-1213								
			Sawyers, Current opinion in Genetics & Development, Vol. 12, 2002, pages 111-115								
			Atallah et al., Cancer, Vol. 94, No. 11, 2002, pages 2996-2999								
			Slamon et al., The New England Journal of Medicine, Vol. 344, No. 11, 2001, pages 783-792								
			Ye et al., Oncogene, Vol. 18, 1999, pages 731-738								
			Ciardiello et al., Clinical Cancer Research, Vol. 5, 1999, pages 909-916								
			Milas et al., Clinical Cancer Research, Vol. 6, 2000, pages 701-708								
			Inoue et al., Clinical Cancer Research, Vol. 6, 2000, pages 4874-4884								
EXAMINER			DATE CONSIDERED								
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.											